Caracterización molecular de la leucemia mieloide crónica atípica y la leucemia neutrofílica crónica
2014; Elsevier BV; Volume: 144; Issue: 11 Linguagem: Espanhol
10.1016/j.medcli.2014.03.020
ISSN1578-8989
AutoresAlicia Senín, Leonor Arenillas, Luz Martínez‐Avilés, Concepción Fernández‐Rodríguez, Beatríz Bellosillo, Lourdes Florensa, Carles Besses, Alberto Álvarez‐Larrán,
Tópico(s)Chronic Myeloid Leukemia Treatments
ResumoAtypical chronic myeloid leukemia (aCML) and chronic neutrophilic leukemia (CNL) display similar clinical and hematological characteristics. The objective of the present study was to determine the mutational status of SETBP1 and CSF3R in these diseases.The mutational status of SETBP1 and CSF3R was studied in 7 patients with aCML (n = 3), CNL (n = 1) and unclassifiable myeloproliferative neoplasms (MPN-u) (n = 3). Additionally, mutations in ASXL1, SRSF2, IDH1/2, DNMT3A, and RUNX1 were also analyzed.SETBP1 mutations (G870S and G872R) were detected in 2 patients with MPN-u, and one of them also presented mutations in SRSF2 (P95H) and ASXL1 (E635fs). The CNL case showed mutations in CSFR3 (T618I), SETBP1 (G870S) and SRSF2 (P95H). No patient classified as aCML had mutations in SETBP1 or CSF3R. One of the patients with mutations evolved to acute myeloid leukemia, while the other 2 had disease progression without transformation to overt leukemia.The knowledge of the molecular alterations involved in these rare diseases is useful in the diagnosis and may have an impact on both prognosis and therapy.
Referência(s)